- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00446381
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) (PEGAP001)
Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME)
Study Overview
Status
Intervention / Treatment
Detailed Description
Diabetes is one of the leading causes of blindness in North America. Diabetic retinopathy (PDR) is characterized by disruption of the normal microvascular circulation in the retina and results in the production of neovascularization and increased microvascular permeability. Similarly, clinically significant diabetic macular edema CSDME) results in loss of central visual acuity.
Many patients with these conditions, despite treatment, will go on to develop vitreous hemorrhage or tractional changes that require surgical intervention (such)as vitrectomy and/or vitrectomy with membrane peeling in the attempt to both restore vision and prevent further visual loss or re-establish the normal macular anatomy and improve patient visual acuity.
Although multiple etiologic factors are involved in the early changes seen in diabetic retinopathy and maculopathy, it has been shown that VEGF is the primary angiogenic growth factor implicated in the development of neovascularization in PRD and in increased vascular permeability, resulting in CSDME. VEGF levels have been found to correlate tightly with the extent of diabetic retinopathy and introduction of VEGF into normal primate eyes can induce diabetic retinopathy. Although several isoforms of VEGF exist, isoform 165 (VEGF 165) is the most pathogenic form of VEGF and therefore inhibition of VEGF 165 may play a significant role in modulating diabetic retinopathy and maculopathy.
Macugen is a VEGF antagonist (anti-VEGF pegylated aptamer) which binds to VEGF 165 with high specificity and affinity. In vitro pharmacology studies have shown that Macugen binds to the amino acid isoform VEGF 165 and inhibits it from binding to its cellular receptors. As a consequence, Macugen blocks signalling events and disrupts the cascade of proliferative and vascular permeability responses associated with the binding of VEGF 165 to endothelial cells. This effect has been clearly proven in Phase 3 trials for patients with age-related macular degeneration (AMD), resulting in inhibition of vascular development and decrease in vascular leakage.
Although diabetic retinopathy represents a different challenge than AMD, the underlying pathogenic factors are similar in the role and effects of VEGF. Regression of retinal neovascularization after Macugen therapy in diabetic individuals has been shown. Phase 2 studies have been completed and Phase 3 studies are currently underway in patients with diabetic macular edema to evaluate the efficacy of Macugen to restore vision in patients with CSDME. These studies are ongoing but exclude patients in whom vitrectomy has been performed or is planned in the near future due to tractional effects on the macula from epiretinal membranes or vitreomacular traction syndrome. No studies have been done to date in patients with PDR or CSDME to quantify the reduction of intravitreal VEGF 165 levels in these patients following intravitreal Macugen injection or to evaluate the effects of VEGF 165 blockade on the neovascular regression and surgical outcome in patients with extensive diabetic proliferative neovascularization.
The goal of this study is to quantify the reduction of intravitreal VEGF 165 levels in patients following intravitreal Macugen injection pre-operatively and determine the level of Macugen in the vitreous cavity after variable time intervals (2,4, 6 or 8 weeks).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4G5
- Ivey Eye Institute, St. Joseph's Health Care Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Type 1 or 2 diabetes
- patients requiring surgical intervention for complications of proliferative diabetic retinopathy with vitreous hemorrhage or traction retinal detachment or clinically significant macular edema
- women postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on effective contraception.
Exclusion Criteria:
- previous retinal vein occlusion.
- any intraocular surgery within the previous 12 months.
- myopia of > or = to 8 diopters.
- active ocular or periocular infection
- treatment with an investigational agent for any condition 60 days prior to enrollment.
- evidence of severe cardiac disease.
- clinically significant peripheral vascular disease (previous surgery, amputation, or symptoms of claudication)
- uncontrolled hypertension (treated systolic blood pressure > 155 mmHg or diastolic blood pressure > 95 mmHg)
- stroke within the preceding 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Patients with Proliferative Diabetic Retinopathy
|
Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
|
Experimental: 2
Patients with Clinically Significant Macular Edema
|
Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Levels of intravitreal Macugen post injection of intravitreal Macugen.
Time Frame: 2 to 8 weeks
|
2 to 8 weeks
|
Levels of intravitreal VEGF 165 pre and post injection of intravitreal Macugen.
Time Frame: 0 to 8 weeks
|
0 to 8 weeks
|
Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1,angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection of intravitreal Macugen.
Time Frame: 0 to 8 weeks
|
0 to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effect on ease of surgery post injection of intravitreal Macugen.
Time Frame: 2 to 8 weeks
|
2 to 8 weeks
|
Effect on re-bleed rate post injection of intravitreal Macugen.
Time Frame: 0 to 8 weeks
|
0 to 8 weeks
|
Effect on concomitant diabetic macular edema post injection of intravitreal Macugen
Time Frame: 0 to 8 weeks
|
0 to 8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas G. Sheidow, MD, Ivey Eye Institute, St. Joseph's Health Care Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R-06-821
- Health Canada Control #108753
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Macugen (pegaptanib)
-
Valley Retina InstituteCompletedDiabetic Macular EdemaUnited States
-
PfizerITEC GROUP 3Completed
-
Eyetech PharmaceuticalsPfizerCompleted
-
Greater Houston Retina ResearchWithdrawn
-
PfizerCompleted
-
Eyetech PharmaceuticalsPfizerUnknownAge-Related Macular Degeneration (AMD)United States
-
L.V. Prasad Eye InstitutePfizerWithdrawnMyopic Choroidal Neovascular MembraneIndia
-
Retina Institute of HawaiiEyetech PharmaceuticalsAvailableDiabetic Macular EdemaUnited States
-
Retina Institute of HawaiiCompleted
-
Eyetech PharmaceuticalsCompleted